| FAMILY/DRUG NAME |
MECHANISM |
COMPANY |
STATUS |
| Interferons -
Mimic naturally-occurring, infection-fighting immune
substance produced in the body |
Intron A
(Interferon
alfa-2b |
Immunomodulator |
Schering-Plough
Madison, NJ |
FDA Approved
1991 |
Pegasys
(Peginterferon alfa-2a) |
Immunomodulator |
Roche
Switzerland |
FDA Approved 2005 |
| There are other brands of interferon
approved for HCV treatment, but they have not been
FDA-approved for HBV: Wellferon (Glaxo), Roferon(Hoffman-La
Roche), and Infergen (Amgen) |
| Nucleoside Analogues
- Interfere with the viral DNA polymerase
enzyme used for hepatitis B virus reproduction |
Epivir-HBV
(Lamivudine) |
Inhibits viral DNA polymerase |
GlaxoSmithKline Philadelphia, PA |
FDA Approved
1998 |
Hepsera
(Adefovir Dipivoxil) |
Inhibits viral DNA polymerase |
Gilead
Foster City, CA |
FDA Approved
2002 |
Baraclude
(Entecavir) |
Inhibits viral DNA polymerase |
Bristol-Myers
Squibb
Princeton, NJ |
FDA Approved
2005
|
Tyzeka
Sebivo (Europe)
(Telbivudine) |
Inhibits viral DNA polymerase |
Idenix
Cambridge, MA |
FDA Approved
2006 |
Viread
(Tenofovir) |
Inhibits viral DNA polymerase |
Gilead
Foster City, CA |
FDA Approved 2008 |
Emtricitabine
(FTC) |
Inhibits viral DNA polymerase |
Gilead
Foster City, CA |
Phase III |
Clevudine
(L-FMAU)
Levovir (S. Korea) |
Inhibits viral DNA polymerase |
Pharmasset
Princeton, NJ
Bukwang
South Korea
Eiasai, Japan |
Phase III, USA
Approved S. Korea (Nov. 2006) |
Valtorcitabine
(monoval LdC) |
Inhibits viral DNA polymerase |
Idenix
Cambridge, MA |
Phase II |
Amdoxovir
(DAPD) |
Inhibits viral DNA polymerase |
RFS Pharm LLC
Tucker, GA |
Phase II |
Pradefovir
(Remofovir)
|
Inhibits viral DNA polymerase |
Schering-Plough
Madison, NJ |
Phase II |
RCV
(Racivir) |
Inhibits viral DNA polymerase |
Pharmasset
Princeton, NJ |
Phase II |
| Non-Nucleoside
Antivirals - Interfere with proteins
involved in viral reproduction |
NOV-205
(BAM 205) |
Small Molecule |
Novelos
Newton, MA |
Approved in Russia |
HepeX-B
(XTL-001) |
Human monoclonal antibodies |
XTL
Biopharm
and Cubist Pharm, Cambridge, MA |
Phase II/III
Orphan drug approval in
US for liver cancer |
| Nitazoxanide (Alinia) |
Small Molecule |
Romark Labs
Tampa, FL |
Phase II Egypt |
UT 231-B
*Discovered by HBF Scientists |
Small Molecule |
United
Therapeutics
Silver Spring, MD |
Preclinical HBV
(Phase II HCV) |
| Bay 41-4109 |
Inhibits viral nucleocapsid |
Bayer
AG
Germany |
Preclinical |
| Non-Interferon
Immune Enhancers - Boost T-cell infection-fighting
immune cells and natural interferon production |
| EHT899 |
Oral Viral Protein |
Enzo
Biochem
New York, N.Y. |
Phase II Israel |
Zadaxin
(Thymosin
alpha-1) |
Immune stimulator |
SciClone
San Mateo, CA |
Orphan drug approval in US for liver cancer |
| Hi-8 HBV |
Therapeutic HBV Vaccine |
Oxxon
U.K. |
Phase II |
| NUC B1000 |
Expressed Interfering RNA |
Nucleonics
Horsham, PA |
Phase I |
| HepaVaxx B |
Therapeutic HBV Vaccine |
Virexx
Canada |
Phase I |
| HBV Core Antigen Vaccine |
Therapeutic HBV Vaccine |
Emergent Europe
U.K.
|
Phase I |
| SpecifEx-HepB |
Immunological Cell Transfer |
Chromos
Burnaby, BC |
Preclinical/
Phase I |
| Post-Exposure
and/or Post-Liver Transplant Treatment |
| HyperHEP S/D |
HBV Immuneglobulin |
Talecris
RTP, NC |
FDA Approved 1977 |
| Nabi-HB |
HBV Immuneglobulin |
Nabi
Boca Raton, FL |
FDA Approved
1999 |
| Hepa Gam B |
HBV Immuneglobulin |
Cangene
Canada |
FDA Approved 2006 |
Cost Comparison of HBV Drugs